Improvement of different vaccine delivery systems for cancer therapy

被引:182
作者
Bolhassani, Azam [1 ]
Safaiyan, Shima [1 ]
Rafati, Sima [1 ]
机构
[1] Pasteur Inst Iran, Mol Immunol & Vaccine Res Lab, Tehran, Iran
来源
MOLECULAR CANCER | 2011年 / 10卷
基金
美国国家科学基金会;
关键词
VIRUS-LIKE PARTICLES; CELL-PENETRATING PEPTIDES; ANTIGEN-PRESENTING CELLS; MEDIATED GENE DELIVERY; DENDRITIC CELLS; IN-VIVO; DNA VACCINATION; IMMUNE-RESPONSE; PLASMID DNA; ANTITUMOR IMMUNITY;
D O I
10.1186/1476-4598-10-3
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cancer vaccines are the promising tools in the hands of the clinical oncologist. Many tumor-associated antigens are excellent targets for immune therapy and vaccine design. Optimally designed cancer vaccines should combine the best tumor antigens with the most effective immunotherapy agents and/or delivery strategies to achieve positive clinical results. Various vaccine delivery systems such as different routes of immunization and physical/chemical delivery methods have been used in cancer therapy with the goal to induce immunity against tumor-associated antigens. Two basic delivery approaches including physical delivery to achieve higher levels of antigen production and formulation with microparticles to target antigen-presenting cells (APCs) have demonstrated to be effective in animal models. New developments in vaccine delivery systems will improve the efficiency of clinical trials in the near future. Among them, nanoparticles (NPs) such as dendrimers, polymeric NPs, metallic NPs, magnetic NPs and quantum dots have emerged as effective vaccine adjuvants for infectious diseases and cancer therapy. Furthermore, cell-penetrating peptides (CPP) have been known as attractive carrier having applications in drug delivery, gene transfer and DNA vaccination. This review will focus on the utilization of different vaccine delivery systems for prevention or treatment of cancer. We will discuss their clinical applications and the future prospects for cancer vaccine development.
引用
收藏
页数:20
相关论文
共 114 条
[41]   DNA vaccines for cervical cancer: from bench to bedside [J].
Hung, Chien-Fu ;
Monie, Archana ;
Alvarez, Ronald D. ;
Wu, T. -C. .
EXPERIMENTAL AND MOLECULAR MEDICINE, 2007, 39 (06) :679-689
[42]   The use of cell-penetrating peptides as a tool for gene regulation [J].
Järver, P ;
Langel, Ü .
DRUG DISCOVERY TODAY, 2004, 9 (09) :395-402
[43]   A membrane-destabilizing peptide in capsid protein L2 is required for egress of papillomavirus genomes from endosomes [J].
Kämper, N ;
Day, PM ;
Nowak, T ;
Selinka, HC ;
Florin, L ;
Bolscher, J ;
Hilbig, L ;
Schiller, JT ;
Sapp, M .
JOURNAL OF VIROLOGY, 2006, 80 (02) :759-768
[44]   Mechanisms used by human papillomaviruses to escape the host immune response [J].
Kanodia, Shreya ;
Fahey, Laura M. ;
Kast, W. Martin .
CURRENT CANCER DRUG TARGETS, 2007, 7 (01) :79-89
[45]   Insertion of interleukin-2 (IL-2) and interleukin-12 (IL-12) genes into vaccinia virus results in effective anti-tumor responses without toxicity [J].
Kaufman, HL ;
Flanagan, K ;
Lee, CSD ;
Perretta, DJ ;
Horig, H .
VACCINE, 2002, 20 (13-14) :1862-1869
[46]   Dendritic cells that endocytosed antigen-containing IgG-liposomes elicit effective antitumor immunity [J].
Kawamura, K ;
Kadowaki, N ;
Suzuki, R ;
Udagawa, S ;
Kasaoka, S ;
Utoguchi, N ;
Kitawaki, T ;
Sugimoto, N ;
Okada, N ;
Maruyama, K ;
Uchiyama, T .
JOURNAL OF IMMUNOTHERAPY, 2006, 29 (02) :165-174
[47]  
Khatri Kapil, 2008, Recent Pat Drug Deliv Formul, V2, P68, DOI 10.2174/187221108783331348
[48]   Cell cycle-dependent association of PML bodies with sites of active transcription in nuclei of mammalian cells [J].
Kiesslich, A ;
von Mikecz, A ;
Hemmerich, P .
JOURNAL OF STRUCTURAL BIOLOGY, 2002, 140 (1-3) :167-179
[49]  
Kim DT, 1997, J IMMUNOL, V159, P1666
[50]   Dendritic cells loaded with exogenous antigen by electroporation can enhance MHC class I-mediated antitumor immunity [J].
Kim, KW ;
Kim, SH ;
Jang, JH ;
Lee, EY ;
Park, SW ;
Um, JH ;
Lee, YJ ;
Lee, CH ;
Yoon, S ;
Seo, SY ;
Jeong, MH ;
Lee, ST ;
Chung, BS ;
Kang, CD .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2004, 53 (04) :315-322